Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 2/3 4Phase 3 3Phase 1 2

Status

Completed 3

Sponsor Class

OTHER 7NIH 3INDUSTRY 3NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Lymphoid 1

Conditions

Carcinoma, Renal Cell 2Lymphoma 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Interferon alpha-2 × Clear all
NCT00738530 2016-06-23

A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Hoffmann-La Roche

Phase 3 Completed
649 enrolled 18 charts
Genitourinary

Carcinoma, Renal Cell

NCT01609010 2014-09-08

A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Hoffmann-La Roche

Phase 3 Completed
313 enrolled 15 charts
Lymphoid

Lymphoma

NCT00083889 2010-01-26

SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma

Pfizer

Phase 3 Completed
750 enrolled 20 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡